University of Crete (UOC)
Οικονομική μελέτη ογκολογικών ασθενών που υποβάλλονται σε ακτινοθεραπεία στο Πανεπιστημιακό Νοσοκομείο Ηρακλείου
Abstract
dc:descriptionAbstract Purpose To estimate the financial burden of radiation therapy (RT) from the perspective of payers, the healthcare system, patients, and society, as well as investigating its impact on quality of life (QoL). The study assessed direct medical and non-medical costs, as well as changes in quality of life, before, during, and up to six months after the completion of radiotherapy. Methods This analysis includes data from 301 cancer patients who underwent radiation therapy (RT) using multiple techniques, including two-dimensional radiation therapy (2D), three-dimensional radiation therapy (3D-CRT), volumetric modulated arc therapy (VMAT), and intensity-modulated radiation therapy (IMRT), at the University General Hospital of Heraklion, Crete. Clinical and cost data were collected retrospectively, while quality-of-life data were collected prospectively using validated instruments at the start of the study, at the end of treatment, and six months after treatment. Quality-adjusted life years (QALYs) were calculated. The main analysis compared radiotherapy with a hypothetical palliative care scenario without radiotherapy based on existing data, while comparisons between radiotherapy techniques were conducted as exploratory analyses. Costs and QALYs were evaluated over a 6-month period; therefore, no discount was applied. At the same time, incremental cost-effectiveness ratios (ICERs) were calculated, and a sensitivity analysis was performed to assess the uncertainty of the results. Results The cost per QALY gained with radiotherapy, compared to palliative care (without radiotherapy), varied significantly depending on the treatment technique and the type of cancer. In the initial analysis, two-dimensional radiotherapy yielded the lowest ICER (€13,043.27/QALY), but VMAT had an ICER of €29,945.12/QALY. In contrast, IMRT showed a significantly higher ICER (€135,529.51/QALY), suggesting a lower cost-effectiveness ratio under standard willingness-to-pay thresholds, while 3D-CRT was deemed the dominant treatment. Subgroup analyses revealed significant heterogeneity, with ICERs ranging from €3,234.45 to €30,232.50 per QALY gained across different cancer types. ConclusionsThe present study, conducted within the Greek healthcare system, suggests that although the 2D-RT technique is associated with lower costs,VMAT demonstrates superior cost-effectiveness and greater clinical benefit.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Vardaki, Elissavet
- Βαρδάκη, Ελισσάβετ
Subjects
dc:subject × 24- Καρκίνος
- Ακτινοθεραπεία
- Οικονομικά της υγείας
- Οικονομική αποτελεσματικότητα
- Ανάλυση κόστους-χρησιμότητας
- Cancer
- Radiotherapy
- Health economics
- Economic evaluation
- Cost-utility analysis
- Άλλες Ιατρικές Επιστήμες
- Ιατρική και Επιστήμες Υγείας
- Ιατρική, άλλοι τομείς
- Οικονομικά και Επιχειρήσεις
- Κοινωνικές Επιστήμες
- Οικονομικά
- Στατιστικές, Πιθανότητες και Αβεβαιότητα
- Other Medical Sciences
- Medical and Health Sciences
- Medicine, miscellaneous
- Economics and Business
- Social Sciences
- Ecomonics
- Statistics, Probability and Uncertainty
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62842